TABLE 2.
Effect of maternal supplementation with 400 mg DHA/d from midpregnancy to delivery on nonfasting serum glucose and lipid concentrations in the offspring at age 4 y1
| DHA (n = 276) | Placebo (n = 248) | P2 | Difference (95% CI)3 | |
| Insulin, μU/mL | 9.6 ± 9.4 | 9.0 ± 8.2 | 0.83 | 0.62 (−0.88, 2.11) |
| Glucose, mg/dL | 93.2 ± 10.3 | 94.0 ± 10.5 | 0.40 | −0.67 (−2.46, 1.11) |
| TGs, mg/dL | 120 ± 66.4 | 121 ± 60.5 | 0.51 | 0.21 (−10.93, 10.52) |
| Total cholesterol, mg/dL | 159. ± 23.6 | 157 ± 27.0 | 0.34 | 1.73 (−2.63, 6.09) |
| HDL cholesterol, mg/dL | 52.0 ± 10.4 | 51.4 ± 9.7 | 0.49 | 0.66 (−1.07, 2.39) |
| Non-HDL cholesterol, mg/dL | 106.7 ± 20.4 | 104.8 ± 21.4 | 0.31 | 1.77 (−1.83, 5.37) |
| LDL cholesterol, mg/dL | 83.9 ± 20.4 | 820.1 ± 23.4 | 0.27 | 1.62 (−2.21, 5.45) |
| apoB, mg/dL | 76.9 ± 14.3 | 76.8 ± 16.3 | 0.90 | −0.15 (−2.78, 2.48) |
| Total-to–HDL cholesterol ratio | 3.1 ± 0.56 | 3.1 ± 0.57 | 0.69 | 0.01 (−0.09, 0.11) |
1
Values are means ± SDs, unless otherwise indicated.
2
From Mann-Whitney test to compare mean differences.
3
Estimates are the differences between the DHA and placebo groups and are derived from multivariable linear regression models, controlling for the time since last food intake and the maternal height.